Immuno-Therapy
common.study.values.description
“An Investigational Immuno-therapy Study of Experimental Medication BMS-986179 Given Alone and in Combination With Nivolumab”
The purpose of this study is to assess the safety and tumor-shrinking ability of experimental medication BMS-986179 alone and when combined with Nivolumab, in patients with solid cancers that are advanced or have spread.
common.study.values.location
participant.ui.study.affiliations-map.online-study.header-virtual
participant.ui.study.affiliations-map.online-study.text
common.study.values.methods
common.study.methods.has-drugs-no
common.study.methods.is-healthy-yes
Biological - BMS-986179
Specified dose on specified days
Biological - Nivolumab
Specified dose on specified days
Biological - rHuPH20
Specified dose on specified days
participant.views.study.view.additional
participant.views.study.view.scientific-title
A Phase 1/2a Study of BMS-986179 Administered Alone and in Combination With Nivolumab (BMS-936558) in Subjects With Advanced Solid Tumors
common.study.values.clinical-trial-id
NCT02754141
participant.views.study.view.id
mepoQd
